Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Azeliragon. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGER known ✓ | Q15109 | 14/20 | 1.00 |
| ▸ | ATP4A | P20648 | 1/20 | 0.49 |
| ▸ | ATP4B | P51164 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1283514 | 1.00 | AGER (1.00) | AGERATP4AATP4BHRH3 | |
| Azeliragon SCHEMBL1893545 | 0.99 | AGER (0.98) | AGERATP4AATP4BHRH3 | |
| Azeliragon SCHEMBL1767579 | 0.96 | AGER (0.91) | AGERATP4AATP4BHRH3 | |
| SCHEMBL1283711 | 0.93 | AGER (0.86) | AGERATP4AATP4BHRH3 | |
| SCHEMBL18650027 | 0.92 | AGER (0.86) | AGERATP4AATP4BHRH3 | |
| SCHEMBL3508025 | 0.92 | AGER (0.86) | AGERATP4AATP4BHRH3 | |
| SCHEMBL1283435 | 0.91 | AGER (0.84) | AGERATP4AATP4BHRH3 | |
| SCHEMBL1283367 | 0.91 | AGER (0.84) | AGERATP4AATP4BHRH3 | |
| SCHEMBL1284076 | 0.91 | AGER (0.86) | AGERHRH3 | |
| SCHEMBL1282589 | 0.91 | AGER (0.83) | AGERHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 439 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4736877-A1 | PHARMACEUTICAL COMPOSITION AND USE THEREOF | The Third Xiangya Hospital of Central South University (CN) | 2026-05-06 | — | — | EP | claimed |
| EP-4736875-A1 | USE OF RAGE RECEPTOR INHIBITOR IN PREPARATION OF DRUG FOR INHIBITING LYMPHOCYTE REDUCTION OR DEATH | The Third Xiangya Hospital of Central South University (CN) | 2026-05-06 | — | — | EP | claimed |
| EP-4676453-A1 | METHODS FOR THE TREATMENT OF FOOD ALLERGY | Institut National de la Santé et de la Recherche Médicale (FR) | 2026-01-14 | — | — | EP | claimed |
| WO-2025217379-A1 | DRUG TREATMENT FOR MACULAR DEGENERATION | UNIVERSITY OF ROCHESTER (US) | 2025-10-16 | — | — | WO | claimed |
| US-20250304565-A1 | NOVEL BENZOFURAN, BENZOTHIOPHENE, AND INDOLE ANALOGS THAT INHIBIT THE FORMATION OF TAU OLIGOMERS AND THEIR METHOD OF USE | Oligomerix Inc. (US) | 2025-10-02 | — | — | US | claimed |
| EP-3562483-B1 | NOVEL BENZOFURAN, BENZOTHIOPHENE, AND INDOLE ANALOGS THAT INHIBIT THE FORMATION OF TAU OLIGOMERS AND THEIR METHOD OF USE | OLIGOMERIX INC (US) | 2025-09-03 | — | — | EP | claimed |
| WO-2025122021-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF), THROUGH TARGETING OF S100A9 AND CORRESPONDING DIMER PARTNER AND RECEPTORS | I3S - INSTITUTO DE INVESTIGAÇÃO E INOVAÇÃO EM SAÚDE, ASSOCIAÇÃO (PT) | 2025-06-12 | — | — | WO | claimed |
| WO-2024191125-A1 | METHOD FOR ACTIVATING ENDOGENOUS NEURAL STEM CELLS THROUGH LOW-INTENSITY FOCUSED ULTRASOUND TREATMENT | 연세대학교 산학협력단 | 2024-09-19 | — | — | WO | claimed |
| EP-4430634-A1 | SYSTEM AND METHOD OF ANALYSING DATA FOR THE DETERMINATION OF THE CONDITION OF A PERSON | Altoida Inc. (US) | 2024-09-18 | — | — | EP | claimed |
| WO-2024184479-A1 | METHODS FOR THE TREATMENT OF FOOD ALLERGY | Institut National de la Santé et de la Recherche Médicale (FR) | 2024-09-12 | — | — | WO | claimed |
| US-20120088778-A1 | AZOLE DERIVATIVES AND FUSED BICYCLIC AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | TRANSTECH PHARMA, INC. (US) | 2012-04-12 | — | — | US | claimed |
| EP-1482931-B1 | MONO- AND BICYCLIC AZOLE DERIVATIVES THAT INHIBIT THE INTERACTION OF LIGANDS WITH RAGE | TRANSTECH PHARMA INC (US) | 2011-10-19 | — | — | EP | claimed |
| US-20110166361-A1 | CRYSTALLINE FORMS OF [3-(4- -PHENOXY)-PROPYL]-DIETHYL-AMINE | TRANSTECH PHARMA, INC. (US) | 2011-07-07 | — | — | US | claimed |
| US-7884219-B2 | Receptor antagonist of advanced glycosylation endproducts ; antiinflammatory agents; Alzheimer's disease; anticancer, antitumor agent; autoimmune disease; antiarthritic agents; multiple sclerosis; diabetic nephropathy; cardiovascular disorders; osteoporosis | TRANSTECH PHARMA, INC. (US) | 2011-02-08 | — | — | US | claimed |
| US-20100256119-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. | 2010-10-07 | — | — | US | claimed |
| US-7737285-B2 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2010-06-15 | — | — | US | claimed |
| US-7714013-B2 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2010-05-11 | — | — | US | claimed |
| US-7361678-B2 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2008-04-22 | — | — | US | claimed |
| US-20070213347-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA (US) | 2007-09-13 | — | — | US | claimed |
| US-20070021386-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA (US) | 2007-01-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256119-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | AGER 1/4885ATP4A 3127/4885ATP4B 3435/4885 |
| US-20250304565-A1 | NOVEL BENZOFURAN, BENZOTHIOPHENE, AND INDOLE ANALOGS THAT INHIBIT THE FORMATION OF TAU OLIGOMERS AND THEIR METHOD OF USE | MAPT, HTT, APP | AGER 806/4885ATP4A 2643/4885ATP4B 2429/4885 |
| US-20070021386-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | AGER 1/4885ATP4A 3159/4885ATP4B 3517/4885 |
| US-20120088778-A1 | AZOLE DERIVATIVES AND FUSED BICYCLIC AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | AGER, S100A4, S100B | AGER 1/4885ATP4A 3159/4885ATP4B 3517/4885 |
| US-20070213347-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | AGER 1/4885ATP4A 3159/4885ATP4B 3517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.